Form 4: Nurix Therapeutics Insider Sells Shares

Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc., sold 5,394 shares of common stock on June 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), reported a transaction on June 25, 2026.
• The transaction involved the sale of 5,394 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan, indicating it was pre-arranged.
• Following the transaction, Hansen beneficially owns 115,005 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a concern, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, mitigating immediate negative sentiment.

Negatives

• Insider selling can sometimes be interpreted as a negative signal by the market, although in this case it was conducted under a pre-arranged trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a report of a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan suggests a planned divestment rather than a reaction to immediate company performance, which is a common practice for executives managing their personal portfolios.

Stakeholder Impact

• Shareholders may note the sale of shares by a key executive, though the Rule 10b5-1 plan context suggests it is a planned divestment and not necessarily a reflection of negative company outlook.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Common Stock, Securities and Exchange Commission